In addition, patients with FRG provide an ideal model for identifying and investigating the pathogenic variants of SLC5A2. SGLT2 inhibitors have attracted attention as therapeutic agents for type 2 diabetes in recent years1, and the analysis of the SLC5A2 gene and examination of the pathophysiology of FRG could provide useful clues to the progress of diabetes and its treatment. Here, SLC5A2 is linked to type 2 diabetes mellitus.